Focus Stocks
Array BioPharma to Present at the Leerink Swann Global Healthcare Conference
Published on Thursday, 09 February 2012 17:35 Written by TradersHuddle Staff
BOULDER, Colo.-( Business Wire )-Array BioPharma Inc. (Nasdaq: ARRY) today announced that its President and Chief Scientific Officer, Kevin Koch, will speak at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
|
Event: |
Leerink Swann Healthcare Conference | ||||
|
Presenter: |
Kevin Koch, Ph.D., President and Chief Scientific Officer | ||||
|
Date: |
Wednesday, February 15, 2012 | ||||
|
Time: |
8:00 a.m. Eastern Time | ||||
|
Location: |
The Waldorf Astoria, New York, NY | ||||
|
Webcast: |
|||||
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.
Related Articles
- Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting
- Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012
- Array BioPharma Names Liam Ratcliffe, M.D., Ph.D., to Board of Directors
- Array BioPharma Names Ron Squarer Chief Executive Officer
- Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012
- Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
- Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer
- Array BioPharma to Present at the Cowen and Company 32nd Annual Health Care Conference
- Array BioPharma Announces Closing of Public Offering of Common Stock and Exercise of Overallotment Option
Related Partner Headlines
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Top 4 Stocks In The Specialty Eateries Industry With The Highest Cash - Benzinga -
Top 4 Small-Cap Stocks In The Security Software & Services Industry With The Highest ROE - Benzinga -
Top 4 Small-Cap Stocks In The Health Care Plans Industry With The Highest Revenue - Benzinga -
Top 4 Small-Cap Stocks In The Heavy Construction Industry With The Lowest PEG Ratio - Benzinga -
Earnings Scheduled For May 25 - Benzinga -
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Syngenta settles atrazine litigation in the USA -
Atrazine Litigation Settled -
eMazzanti Attains Xerox Gold Partner Status -
USFS, BLM Hire Youth for Public Lands Conservation Jobs -
SCVBank Elects Scott K. Rushing as New Chairman -
Heritage Oaks Bancorp to Pay Trust Preferred Interest and Accumulated TARP Dividends -
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012









